Cancer diagnostics company GENCURIX said on the 2nd that it signed a strategic exclusive distribution agreement with Bio-Rad Laboratories, headquartered in California, to supply the digital PCR-based tumor diagnostic kit "Droplex™" to Europe.
"Droplex™" is a product the two companies co-developed, incorporating Bio-Rad's technology. It can sensitively detect gene mutations that are critical for cancer diagnosis and treatment decisions from tissue samples and liquid biopsy specimens in major cancers such as lung cancer, colorectal cancer, and melanoma.
GENCURIX said, "With this agreement, the two companies have further strengthened their existing partnership," adding, "While pushing for commercialization across Europe, we also plan to carry out joint marketing activities and collaborate on product development."